Enhancing complement control on endothelial barrier reduces renal post-ischemia dysfunction - PubMed (original) (raw)
Enhancing complement control on endothelial barrier reduces renal post-ischemia dysfunction
Sathnur B Pushpakumar et al. J Surg Res. 2011 Oct.
Abstract
Background: Excessive complement activation is an integral part of ischemia and reperfusion (IR) injury (IRI) of organs. In kidney transplantation, the pathologic consequence of IRI and complement activation can lead to delayed graft function, which in turn is associated with acute rejection. Previous strategies to reduce complement-induced IRI required systemic administration of agents, which can lead to increased susceptibility to infections/immune diseases. The objective of this study was to determine whether an increase in complement control defenses of rat kidney endothelium reduces IRI. We hypothesized that increased complement control on the endothelial barrier reduces IR-mediated complement activation and reduces kidney dysfunction.
Materials and methods: Fischer 344 rats underwent left kidney ischemia for 45 min and treatment with a novel fusogenic lipid vesicle (FLVs) delivery system to decorate endothelial cells with vaccinia virus complement control protein (VCP), followed by reperfusion for 24 h. Assessment included renal function by serum creatinine and urea, myeloperoxidase assay for neutrophil infiltration, histopathology, and quantification of C3 production in kidneys.
Results: Animals in which the kidney endothelium was bolstered by FLVs+VCP treatment had better renal function with a significant reduction in serum creatinine compared with vehicle controls (P < 0.05). Also, C3 production was significantly reduced (P < 0.05) in treated animals compared with vehicle controls.
Conclusion: Increasing complement control at the endothelial barrier with FLVs+VCP modulates complement activation/production during the first 24 h, reducing renal dysfunction following IRI.
Copyright © 2011 Elsevier Inc. All rights reserved.
Conflict of interest statement
The authors Sathnur Pushpakumar, Chirag Soni, Rong Wan, Nathan Todnem, Phani K Patibandla, Tathyana Fensterer, Qunwei Zhang, John H. Barker, do not have any conflict of interest.
Figures
Figure 1
Animals treated with FLVs+VCP (Fusogenic lipid vesicles and Vaccinia virus complement control protein) maintain better renal function. Creatinine was analyzed from blood samples collected before inducing IRI and after 24h of reperfusion. Control animals which received lactated Ringer’s solution only, show 7 fold increase in serum creatinine as compared to <3 fold in the FLVs+VCP group (*P<0.05). Values are represented as means±SEM (n=6/group).
Figure 2
There was no difference in the serum urea levels between the groups. Serum urea was measured similar to creatinine as described in Figure 1. Values are represented as means±SEM (n=6/group).
Figure 3
Kidney samples were collected as described in the materials and methods section. Kidney injury was scored according to Jablonski’s criteria Grades 1–4. Representative histology pictures at 20x from: a) sham rats, b) control kidney (lactated Ringer’s solution perfusion) shows extensive damage of the tubules and glomeruli including necrosis (arrows), c) FLVs+VCP treated kidney shows preservation of normal architecture with moderate tubular damage (arrow) and lesser neutrophil infiltration, d) VCP treated animal shows minimal damage and decreased neutrophil infiltration, and e) FLVs treated kidney shows moderate injury and neutrophil infiltration.
Figure 4
Effect of treatments on MPO activity as a marker for neutrophil infiltration into the tissues. VCP therapy by itself shows significantly reduced MPO activity (P<0.05) and treatment with FLVs+VCP and FLVs shows a downward trend. Control group shows increased levels indicating marked neutrophil influx. Values are represented as means±SEM (n=6/group).
Figure 5
A. Graph of Western blot analysis comparing the deposition of C3 in kidneys from all groups (n=3/group). Excessive C3 deposits in the kidney homogenates was significantly decreased in the FLVs+VCP treated group as compared to control (P<0.05). B. Representative blot from a complete set of experiments.
Similar articles
- Blockade of the G-CSF Receptor Is Protective in a Mouse Model of Renal Ischemia-Reperfusion Injury.
McRae JL, Vikstrom IB, Bongoni AK, Salvaris EJ, Fisicaro N, Ng M, Alhamdoosh M, Baz Morelli A, Cowan PJ, Pearse MJ. McRae JL, et al. J Immunol. 2020 Sep 1;205(5):1433-1440. doi: 10.4049/jimmunol.2000390. Epub 2020 Jul 27. J Immunol. 2020. PMID: 32839213 - Vaccinia virus complement control protein (VCP) improves kidney structure and function following ischemia/reperfusion injury in rats.
Ghebremariam YT, Engelbrecht G, Tyler M, Lotz Z, Govender D, Kotwal GJ, Kahn D. Ghebremariam YT, et al. J Surg Res. 2010 Apr;159(2):747-54. doi: 10.1016/j.jss.2009.04.049. Epub 2009 Jun 6. J Surg Res. 2010. PMID: 19691975 - Overexpression of Human CD55 and CD59 or Treatment with Human CD55 Protects against Renal Ischemia-Reperfusion Injury in Mice.
Bongoni AK, Lu B, Salvaris EJ, Roberts V, Fang D, McRae JL, Fisicaro N, Dwyer KM, Cowan PJ. Bongoni AK, et al. J Immunol. 2017 Jun 15;198(12):4837-4845. doi: 10.4049/jimmunol.1601943. Epub 2017 May 12. J Immunol. 2017. PMID: 28500075 - Extracellular Vesicles as Mediators of Cellular Crosstalk Between Immune System and Kidney Graft.
Quaglia M, Dellepiane S, Guglielmetti G, Merlotti G, Castellano G, Cantaluppi V. Quaglia M, et al. Front Immunol. 2020 Feb 27;11:74. doi: 10.3389/fimmu.2020.00074. eCollection 2020. Front Immunol. 2020. PMID: 32180768 Free PMC article. Review. - The interaction between ischemia-reperfusion and immune responses in the kidney.
Jang HR, Ko GJ, Wasowska BA, Rabb H. Jang HR, et al. J Mol Med (Berl). 2009 Sep;87(9):859-64. doi: 10.1007/s00109-009-0491-y. Epub 2009 Jun 28. J Mol Med (Berl). 2009. PMID: 19562316 Review.
Cited by
- C4d Deposition after Allogeneic Renal Transplantation in Rats Is Involved in Initial Apoptotic Cell Clearance.
Reuter S, Kentrup D, Grabner A, Köhler G, Buscher K, Edemir B. Reuter S, et al. Cells. 2021 Dec 10;10(12):3499. doi: 10.3390/cells10123499. Cells. 2021. PMID: 34944007 Free PMC article. - Rapid Lipid Modification of Endothelial Cell Membranes in Cardiac Ischemia/Reperfusion Injury: a Novel Therapeutic Strategy to Reduce Infarct Size.
Maldonado C, Nguyen MD, Bauer P, Nakamura S, Khundmiri SJ, Perez-Abadia G, Stowers HL, Wu WJ, Tang XL. Maldonado C, et al. Cardiovasc Drugs Ther. 2021 Feb;35(1):113-123. doi: 10.1007/s10557-020-07101-x. Epub 2020 Oct 20. Cardiovasc Drugs Ther. 2021. PMID: 33079319 Free PMC article. - Effect of Hyperbaric Oxygen on Tissue Damage and Expression of Adhesion Molecules and C3 in a Rat Model of Renal Ischemia-Reperfusion Injury After Kidney Transplantation.
Zhao F, Wang X, Liang T, Bao D, Wang Y, Du Y, Li H, Du J, Chen A, Fu Z, Xie Z, Liang G. Zhao F, et al. Ann Transplant. 2020 Jun 5;25:e919385. doi: 10.12659/AOT.919385. Ann Transplant. 2020. PMID: 32499475 Free PMC article. - C3a receptor antagonist therapy is protective with or without thrombolysis in murine thromboembolic stroke.
Ahmad S, Pandya C, Kindelin A, Bhatia K, Chaudhary R, Dwivedi AK, Eschbacher JM, Liu Q, Waters MF, Hoda MN, Ducruet AF. Ahmad S, et al. Br J Pharmacol. 2020 Jun;177(11):2466-2477. doi: 10.1111/bph.14989. Epub 2020 Mar 4. Br J Pharmacol. 2020. PMID: 31975437 Free PMC article. - Opportunities for Therapeutic Intervention During Machine Perfusion.
Karimian N, Yeh H. Karimian N, et al. Curr Transplant Rep. 2017 Jun;4(2):141-148. doi: 10.1007/s40472-017-0144-y. Epub 2017 Apr 19. Curr Transplant Rep. 2017. PMID: 29109929 Free PMC article.
References
- Farrar CA, Zhou W, Lin T, Sacks SH. Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J. 2006;20:217–226. - PubMed
- Yamada K, Miwa T, Liu J, Nangaku M, Song WC. Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J Immunol. 2004;172:3869–3875. - PubMed
- Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol. 2003;170:1517–1523. - PubMed
- Carter AM, Prasad UK, Grant PJ. Complement C3 and C-reactive protein in male survivors of myocardial infarction. Atherosclerosis. 2009;203:538–543. - PubMed
- Distelmaier K, Adlbrecht C, Jakowitsch J, Winkler S, Dunkler D, Gerner C, Wagner O, Lang IM, Kubicek M. Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb Haemost. 2009;102:564–572. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R41 HL079855/HL/NHLBI NIH HHS/United States
- R42 HL079855-03/HL/NHLBI NIH HHS/United States
- R42 HL079855/HL/NHLBI NIH HHS/United States
- R41HL079855/HL/NHLBI NIH HHS/United States
- R42 HL079855-02A1/HL/NHLBI NIH HHS/United States
- R41 HL079855-01/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous